Hogan Lovells adds three in Greater China

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Hogan Lovells adds three in Greater China

Partners Alan Chiu and Eugene Low along with consultant Kenny Wong join Hogan Lovells’ Hong Kong office

All three come from Mayer Brown JSM in Hong Kong. Chiu’s practice focuses on IP litigation as well portfolio management and licensing matters in both Hong Kong and China. He is also experienced with anti-counterfeiting matters and domain name cases.

Low’s practice also focuses on litigation in Hong Kong and China. He has experience in technology licensing and disputes, copyright clearance matters and data privacy issues.

Wong also has a contentious-focused practice, and is experienced in commercial IP matters. He previously served as the head of Mayer Brown JSM’s Asia IP-IT practice.

more from across site and SHARED ros bottom lb

More from across our site

The team, comprising two partners and one senior consultant, plans to offer “highly differentiated” services to clients
HGF’s new ownership model frees it from the hiring constraints of traditional partnerships, its CEO told Managing IP
New timeline for 2026 aims to provide clearer guidance to firms and practitioners on the full jurisdictional market view
Attorneys contemplate whether clients using AI for legal guidance is beneficial to attorney-client relationships or more of a nuisance
Richard de Bodo, who had a lengthy career at international firms, shares how he will address client needs and praises the unique offerings of smaller firms
An Australian top court decision clarifying honest concurrent use and wins by publishers against AI platforms were also among the top talking points
AIPPI has pulled the plug on its planned 2027 World Congress, and INTA has delayed hosting a meeting there, but the concerns won’t abate
Despite being outspent by a wealthy opponent, a trial attorney at King & Spalding says ‘relentless pursuit of the truth’ helped his team secure a $420m damages award for mobile gaming client
190 drugs face loss of exclusivity between 2026 and 2030, with the list including Bristol Myers Squibb’s blood-thinning drug Eliquis and immunotherapy medication Opdivo
Nokia, represented by a team from Bird & Bird, adjudged to have made fair offer to Asus and Acer in UK SEP dispute
Gift this article